[1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists
View Patent ↗Compounds having the structural formula I wherein: n is 0, 1, 2 or 3; A is C(R 1 ) or N; R 1 and R 1a are H, (C 1 -C 6 )-alkyl, halo, CN or —CF 3 ; X is —C(O)—, —O—, —SO 0-2 —, or optionally substituted methylene, imino, arylene or heteroaryldiyl; Y is —O—, —SO 0-2 —, or optionally substituted arylene, heteroaryldiyl, or nitrogen-containing heterocycloalkyl, or with certain provisos, a bond; R is optionally substituted-aryl or heteroaryl; and R 2 is optionally substituted aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R 2 —Y is a fused piperidinyl, substituted piperazinyl or substituted piperidinyl; their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.
1. A compound represented by the structural formula
or a pharmaceutically acceptable salt thereof, wherein:
A is N;
R 1 and R 1a are independently selected from the group consisting of H, (C 1 -C 6 )-alkyl, halo, CN and —CF 3 ;
Y is —O—, —S—, —SO—, —SO 2 —, R 5 -heteroaryldiyl, R 5 -arylene or
p and q are independently 2-3;
Q and Q 1 are independently selected from the group consisting of
provided that at least one of Q and Q 1 is
R is R 5- aryl, R 5- heteroaryl, R 6 —(C 2 -C 6 )alkenyl or R 8- (C 2 -C 6 )alkynyl;
R 2 is R 5 -aryl, R 5- heteroaryl, R 5- aryl(C 1 -C 6 )alkyl or R 5- heteroaryl(C 1 -C 6 )alkyl; or R 2 —Y is
U, V, and W are independently selected from the group consisting of N and CR 1 , provided that at least one of U, V and W is CR 1 ;
n is 1, 2 or 3; and
(a) X is —N(R 9 )—, Y is R 5 -arylene and R 2 is
or n is 2 or 3; and
(b) X is —C(R 3 )(R 3a )—, —C(O)—, —O—, —S—, —SO—, —SO 2 —, —N(R 9 )—, R 4 -arylene or R 4 -heteroaryldiyl; or Y is a bond and X is —C(O)—, —N(R 9 )—, R 4 -arylene or R 4 -heteroaryldiyl; or Y is —N(R 9a )—, —C(O)N(R 9a )— or —O—(CH 2 ) 2 —N(R 9a )—, and X is —N(R 9 )—; or X is —N(R 9 )—, and Y and R 2 together are
or n is 0; and
(c) Y is a bond, X is —N(R 9 )—, and R 2 is
(d) X is —N(R 9 )— and Y and R 2 together are
wherein Z is —C(O)—CH 2 —, —C(O)—CH(C 1 -C 8 alkyl)—, —CH 2 —CH(C 1 -C 8 alkyl)—, or —CH(C 1 -C 6 alkyl)—CH 2 —;
R 3 and R 3a are independently selected from the group consisting of H, —OH, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl and di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl;
R 4 is 1-3 substituents selected from the group consisting of H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , and —CN;
R 5 is 1-3 substituents independently selected from the group consisting of H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , —CN, —NH 2 , (C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkanoyl-amino, (C 1 -C 6 )alkanesulfonyiamino, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylthio(C 1 -C 6 )alkyl, R 6 —(C 2 -C 6 )alkenyl, R 6 —(C 2 -C 6 )alkynyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-C(O)-amino, or heterocycloalkyl(C 1 -C 6 )alkyl;
R 6 is 1 to 3 substituents independently selected from the group consisting of H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy and halo;
R 7 and R 7a are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, R 6 -aryl and R 6 -heteroaryl, or an R 7 and an R 7a substituent on the same carbon can form ═O;
R 8 is 1 to 3 substituents independently selected from H, (C 1 -C 6 )alkyl, —OH, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy, halo, —CF 3 , and —CN;
R 9 and R 9a are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, hydroxy(C 2 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 2 -C 6 )alkyl, amino(C 2 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 2 -C 6 )alkyl, di(C 1 -C 6 )alkylamino(C 2 -C 6 )alkyl, halo-(C 3 -C 6 )alkenyl, CF 3 —(C 1 -C 6 )alkyl, (C 3 -C 6 )alkenyl, —(C 3 -C 6 )cycloalkyl and (C 3 -C 6 )cycloalkyl-(C 1 -C 6 )alkyl; and
R 10 is H, —C(O)—O—(C 1 -C 6 )alkyl, R 5 -aryl, —C(O)—(C 1 —C 6 )alkyl, —C(O)—(R 5 -aryl) or R 5 -aryl-(C 1 -C 6 )alkyl.
2. The compound of claim 1 wherein X is —O—, —S—, —N(R 9 )— or R 4 -arylene.
3. The compound of claim 2 wherein R 9 is methyl or ethyl.
4. The compound of claim 1 wherein Y is a bond or piperazinyl.
5. The compound of claim 1 wherein R 2 is R 5 -aryl.
6. The compound of claim 1 wherein R is furyl.
7. The compound of claim 1 wherein X is —O—, —S—, —N(R 9 )— or R 4 -arylene; R 9 is methyl or ethyl; Y is a bond or piperazinyl; R 2 is R 5 -aryl; and R is furyl.
8. The compound of claim 7 wherein R 5 is 1 or 2 substituents selected from the group consisting of H, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )-alkoxy, halo and CF 3 .
9. A compound of claim 1 selected from the group consisting of compounds of the formula
wherein R 2 —Y—(CH 2 ) n —N(R 9 )— is as defined in the table and Me means methyl:
R 2 —Y—(CH 2 ) n —N(R 9 )—
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
11. A method of treating depression comprising administering an effective amount of a compound of claim 1 to a mammal in need of such treatment.